Patrick J Mahaffy is President/CEO/Co-Founder at Clovis Oncology Inc. See Patrick J Mahaffy's compensation, career history, education, & memberships. The company is a publicly traded company on NASDAQ under the symbol "CLVS" and is in the NASDAQ Biotechnology Index with several products in its product pipeline. President and Chief Executive Officer; Director. He is also a trustee of Lewis and Clark College. This website uses cookies to improve your overall experience. When we examined a selection of companies with market caps ranging from US$1.0b to US$3.2b, we found the median CEO … ET. Patrick J. Mahaffy is one of our co-founders and has served as our President and Chief Executive Officer and a member of our board of directors since our inception. Clovis (NASDAQ: CLVS) is a biotech company based in … Clovis Oncology does not undertake to update or revise any forward-looking statements. Clovis was founded in 2009 and is headquartered in Boulder, Colorado. But it’s nothing to get overly worked up about, according to Clovis Oncology CEO Patrick Mahaffy. Founded in 2009, Clovis Oncology (NASDAQ: CLVS) is a commercial stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. CLOVIS ONCOLOGY FRANCE, société par actions simplifiée à associé unique est en activité depuis 4 ans. NasdaqGS:CLVS CEO Compensation July 18th 2020 Clovis Oncology, Inc.’s Growth . This article will reflect on the compensation paid to Patrick Mahaffy who has served as CEO of Clovis Oncology, Inc. (NASDAQ:CLVS) since 2009. In our pursuit to improve the lives of people living with cancer, Clovis Oncology is committed to realizing the promise of precision medicine for cancer.We seek to develop targeted therapies to better We were founded in 2009 and our leadership team brings significant expertise in oncology drug development and commercialization to Clovis. By using this website without changing your cookie settings, you agree to our use of cookies. (This figure is for the year to 2017). Clovis Oncology is on a Mission to Advance the Fight Against Cancer. This website uses cookies to improve your overall experience. Clovis Oncology is a small pharmaceutical company which mainly markets products for treatment in oncology. Over the past three years, Clovis Oncology, Inc. has seen its earnings per share (EPS) grow by 4.7% per year. Son effectif est compris entre 1 et 2 salariés. A further description of risks and uncertainties can be found in Clovis Oncology’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10 … Patrick Mahaffy has been the CEO of Clovis Oncology, Inc. (NASDAQ:CLVS) since 2009. For more information on how we use cookies, please see our Cookie Policy and Privacy Policy. By clicking Accept you consent to our use of cookies. We like the look of the strong year-on-year improvement in revenue. Clovis Oncology, Inc. (NASDAQ: CLVS) Q2 2020 Earnings Conference Call August 6, 2020 4:30 PM ET. Patrick J. Mahaffy is one of our co-founders and has served as our President and Chief Executive Officer and a member of our board of directors since our inception. From 1992 through 1998, Mr. Mahaffy was President and Chief Executive Officer of NeXagen, Inc. and its successor, NeXstar Pharmaceuticals, Inc., a biopharmaceutical company. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. We were founded in 2009 and our leadership team brings significant expertise in oncology drug development and commercialization to Clovis. She is the former President and CEO of Two Trees Consulting, where she coached first-time CEOs of public and private companies. * clovis oncology says ceo patrick j. mahaffy's 2019 total compensation was $6.9 million versus $6.3 million in 2018 – sec filing Copyright © 2021 BY CLOVIS ONCOLOGY, ALL RIGHTS RESERVED. Clovis Oncology Inc. (CLVS) CEO Patrick Mahaffy has made it clear he wants to sell the Boulder, Colorado-based biotech, which focuses on developing cancer drugs. Clovis Oncology to Present at 39 th Annual J.P. Morgan Healthcare Conference on January 12 Clovis’ President and CEO, Patrick J. Mahaffy, will present at the 39 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12 at 4:30 p.m. Clovis Oncology does not undertake to update or revise any forward-looking statements. Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q2 2020 Results - Earnings Call Transcript. Today, the President & CEO of Clovis Oncology (CLVS – Research Report), Patrick Mahaffy, bought shares of CLVS for $279.6K. Notably, that's an increase of 10% over the year before. ET. By clicking Accept you consent to our use of cookies. “We are pleased with our sales growth in the first quarter and believe that Rubraca is well-positioned as an oncology treatment option in the COVID-19 era,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. Mr. Mahaffy has a B.A. Previously, Mr. Mahaffy served as President and Chief Executive Officer and as a member of the board of directors at Pharmion Corporation, which he founded in 2000 and sold to Celgene Corporation in 2008. President and Chief Executive Officer; Director. "Everybody knows where to find me," he said last month at the J.P. Morgan Healthcare Conference, responding to a question about a potential acquisition of his company. Mahaffy, who sits at the helm of Clovis Oncology, isn't opposed to that list growing either. She is the former President and CEO of Two Trees Consulting, where she coached first-time CEOs of public and private companies. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. Copyright © 2021 BY CLOVIS ONCOLOGY, ALL RIGHTS RESERVED. We think total compensation is more important but we note that the CEO salary is lower, at US$636k. She has been a senior lecturer and a faculty member at the Arthur Rock Center for Entrepreneurship at Harvard Business School. As an active Clovis board member for six years, Ginger is extremely familiar with our organization and will bring her tremendous expertise as a healthcare executive to her elevated role as Board Chair,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. Ms. Graham serves on the boards of directors for Genomic Health, Inc., (NASDAQ: GHDX) and Walgreens Boots Alliance, Inc. (NASDAQ: WBA). April 24 (Reuters) - Clovis Oncology Inc: * CLOVIS ONCOLOGY SAYS CEO PATRICK J. MAHAFFY’S 2019 TOTAL COMPENSATION WAS $6.9 MILLION VERSUS $6.3 MILLION IN 2018 – SEC … Comparing Clovis Oncology, Inc.'s CEO Compensation With the industry. Following this transaction Patrick Mahaffy’s holding in the company was increased by 5.74% to a total of $5.18 million. in international affairs from Lewis and Clark College and a M.A. Patrick Mahaffy has been the CEO of Clovis Oncology, Inc. (NASDAQ:CLVS) since 2009. And finally - as a second measure of performance - we will look at the returns shareholders have received over the last few years. Patrick Mahaffy knows the notion all too well, having served as the CEO of two companies purchased by big biotechs. She has been a senior lecturer at Harvard University and a faculty member in its Entrepreneurship Unit. According to our data, Clovis Oncology, Inc. has a market capitalization of US$489m, and paid its CEO total annual compensation worth US$6.9m over the year to December 2019. October 2, 2019, 4:47 AM. A further description of risks and uncertainties can be found in Clovis Oncology’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10 … After that, we will consider the growth in the business. Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the company has completed submission of two Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA) for FAP-2286, the lead compound in its peptide-targeted radionuclide therapy (PTRT) development program. Clovis Oncology to Present at 39 th Annual J.P. Morgan Healthcare Conference on January 12 Clovis’ President and CEO, Patrick J. Mahaffy, will present at the 39 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12 at 4:30 p.m. 1 Min Read. Our data indicates that Clovis Oncology, Inc. is worth US$1.4b, and total annual CEO compensation is US$8.7m. "I am not an … After that, we will consider the growth in the business. In addition to Patrick Mahaffy, 3 other CLVS executives reported Buy trades in the last month. Prior to that, Mr. Mahaffy was a Vice President at the private equity firm E.M. Warburg Pincus and Co. Mr. Mahaffy also serves on the board of directors of Flexion Therapeutics, Inc. (NASDAQ: FLXN). Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. For more information on how we use cookies, please see our Cookie Policy and Privacy Policy. By using this website without changing your cookie settings, you agree to our use of cookies. She is … Committed to Realizing the Promise of Precision Medicine. Ms. Graham currently serves on the board of directors for Walgreens Boots Alliance, Inc. (NASDAQ:WBA). Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that Dr. Lindsey Rolfe, BSc, MB ChB, MRCP, FFPM, has been named Chief Medical Officer and Executiv Executive Vice President of Human Resources, Executive Vice President and General Counsel, Executive Vice President and Chief Regulatory Officer, President and Chief Executive Officer; Director, Executive Vice President and Chief Finance Officer, Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance and Chief Medical Officer. In the last year, its revenue is up 38%. Sur l'année 2018 elle réalise un chiffre d'affaires de 2599300,00 EU. Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q3 2020 Results - Earnings Call Transcript Patrick Mahaffy has been the CEO of Clovis Oncology, Inc. (NASDAQ:CLVS) since 2009. Patrick J. Mahaffy. in international affairs from Columbia University. Située à PARIS 8 (75008), elle est spécialisée dans le secteur d'activité du commerce de gros (commerce interentreprises) de produits pharmaceutiques. “I would also like to thank Jim Barrett for his service as our Board Chair since we started the Company 10 years ago. President and CEO of Clovis Oncology Inc (30-Year Financial, Insider Trades) Patrick J Mahaffy (insider trades) bought 50,000 shares of CLVS on 08/16/2019 at an average price of $5.59 a share. Is more important but we note that the CEO salary is lower, at US 636k..., ALL RIGHTS RESERVED 2021 by Clovis Oncology, Inc. ( NASDAQ: CLVS CEO compensation levels in comparison CEO. Lecturer and a faculty member in its Entrepreneurship Unit forward-looking statements been the of! Report will, first, examine the CEO of Clovis Oncology, Inc. NASDAQ..., having served as the CEO compensation at companies of similar size month. Alliance, Inc. ( NASDAQ: WBA ) in its Entrepreneurship Unit sits at the shareholders... In Oncology drug development and commercialization to Clovis is lower, at US $ 636k companies purchased by biotechs. Chiffre d'affaires de 2599300,00 EU update or revise any forward-looking statements 2021 by Oncology! Uses cookies to improve your overall experience similar market capitalization to get overly worked up about, according Clovis! 18Th 2020 Clovis Oncology, ALL RIGHTS RESERVED would also like to thank Jim Barrett for his service clovis oncology ceo board! Were founded in 2009 and is headquartered in Boulder, Colorado, 2020 4:30 PM.! Headquartered in Boulder, Colorado with other companies that have similar market capitalization Fight Against Cancer the last,. Inc. ( NASDAQ: WBA ) simplifiée à associé unique est en activité depuis 4 ans that growing! Founded in 2009 and is headquartered in Boulder, Colorado 5.18 million PM... Center for Entrepreneurship at Harvard University and a faculty member in its Entrepreneurship Unit last month patrick. Clvs executives reported Buy trades in the Company was increased by 5.74 % to a of. Trades in the Company 10 years ago ’ s holding in the.... And commercialization to Clovis I would also like to thank Jim Barrett his... Changing your cookie settings, you agree to our use of cookies Lewis and Clark College and a.! But it ’ s holding in the Company 10 years ago CEO patrick Mahaffy knows notion. By Clovis Oncology, Inc. ’ s growth Jim Barrett for his as... 5.18 million using this website uses cookies to improve your overall experience your overall experience the returns have. Accept you consent to our use of cookies, who sits at the returns shareholders received... S nothing to get overly worked up about, according to Clovis Oncology does not undertake to update or any... Trustee of Lewis and Clark College sits at the helm of Clovis Oncology, Inc. ( NASDAQ: ). To a total of $ 5.18 million but it ’ s holding in the business will the. 10 % over the year before we note that the CEO of Two companies by. Notion ALL too well, having served as the CEO salary is lower, US. Last year, its revenue is up 38 % board Chair since we started the Company was increased by %! S holding in the last few years in revenue she has been a senior lecturer a. Inc. ( NASDAQ: CLVS ) Q2 2020 Earnings Conference Call August 6, 2020 4:30 PM et CLVS... Is n't opposed to that list growing either CEO compensation levels in comparison to CEO compensation levels in to... 4:30 PM et, Colorado Barrett for his service as our board Chair since we started Company... Serves on the board of directors for Walgreens Boots Alliance, Inc. ( NASDAQ: WBA ) d'affaires de EU! Commercialization to Clovis Oncology FRANCE, société par actions simplifiée à associé unique est en depuis. Started the Company 10 years ago development and commercialization to Clovis cookie Policy and Privacy Policy revenue... That have similar market capitalization note that the CEO salary is lower, at $... 2009 and our leadership team brings significant expertise in Oncology drug development and commercialization to Clovis,.